Saturday, 31 October 2026European Markets

TERACT Stock Impressive Jump On Monday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with teract (tract.pa) rising 15.67% to €0.69 on monday, following the last session's downward trend. cac 40 fell 0.2% to €8,148.14, after four consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

teract's last close was €0.60, 91.98% below its 52-week high of €7.48.

about teract

teract s.a. operates in retail business in europe. the company operates through garden centre retailer and marketer segments. it operates garden centers and pet care shops under the jardiland, gamm vert, delbard, and jardinerie du terroir brand names. the company also operates in the fresh, local, and organic produce sector under frais d'ici and bio&co brands with food outlets. it operates 1,597 stores. the company is based in paris, france.

earnings per share

as for profitability, teract has a trailing twelve months eps of €0.62.

pe ratio

teract has a trailing twelve months price to earnings ratio of 1.12. meaning, the purchaser of the share is investing €1.12 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -36.98%.

yearly top and bottom value

teract's stock is valued at €0.69 at 21:35 est, way under its 52-week low of €1.87.

volume

today's last reported volume for teract is 121379 which is 181.77% above its average volume of 43077.

more news about teract (tract.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com